Last reviewed · How we verify
HM11260C
HM11260C is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
HM11260C is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers. Used for Hormone receptor-positive, HER2-negative breast cancer.
At a glance
| Generic name | HM11260C |
|---|---|
| Also known as | LAPS-Exendin-4, LAPS-Exendin4 |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | Selective Estrogen Receptor Degrader (SERD) |
| Target | Estrogen Receptor (ER) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a SERD, HM11260C binds to the estrogen receptor with high affinity and promotes its proteasomal degradation, eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism differs from selective estrogen receptor modulators (SERMs) by achieving complete receptor elimination rather than partial antagonism, potentially overcoming resistance mechanisms in hormone receptor-positive breast cancer.
Approved indications
- Hormone receptor-positive, HER2-negative breast cancer
Common side effects
- Hot flashes
- Fatigue
- Nausea
- Vaginal dryness
Key clinical trials
- A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin (PHASE3)
- A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus (PHASE3)
- Effect of LAPS-Exendin on Body Weight in Obese Population (PHASE2)
- Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus (PHASE2)
- Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes (PHASE2)
- Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes (PHASE2)
- A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus (PHASE1)
- A Study of HM11260C in Healthy Male Subject (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HM11260C CI brief — competitive landscape report
- HM11260C updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI